Chad Manuel, MD
Family Medicine · Lafayette, LANPI 1316967367
Payments from drug & device makers
Across 208 payments — averaging $20.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$706
- Novo Nordisk$654
- Pfizer$605
- Otsuka America Pharmaceutical, Inc.$252
- Philips North America LLC$240
- GSK$236
- plus $2K from 24 others
What the payments were for
- Food & beverage$4,341100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 49 | $706 |
| Novo Nordisk | 34 | $654 |
| Pfizer | 30 | $605 |
| Otsuka America Pharmaceutical, Inc. | 6 | $252 |
| Philips North America LLC | 5 | $240 |
| GSK | 8 | $236 |
| Antares Pharma, Inc. | 6 | $194 |
| Exact Sciences | 8 | $156 |
| Ironwood Pharmaceuticals, Inc | 5 | $139 |
| Abbott | 1 | $133 |
| Lilly USA, LLC | 7 | $126 |
| AstraZeneca | 6 | $102 |
| Phathom Pharmaceuticals, Inc. | 6 | $96 |
| Tolmar, Inc. | 5 | $92 |
| Teva Pharmaceuticals USA, Inc. | 1 | $85 |
| Amgen | 5 | $84 |
| Novartis | 4 | $70 |
| Bayer | 4 | $67 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $56 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $34 |
| Neos Therapeutics, LP | 2 | $31 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $30 |
| Sanofi Pasteur Inc. | 2 | $23 |
| Lundbeck LLC | 1 | $23 |
| Biogen | 1 | $21 |
| Johnson & Johnson | 1 | $20 |
| Phadia US Inc. | 1 | $19 |
| Boehringer Ingelheim | 1 | $17 |
| Upsher-smith Laboratories LLC | 1 | $15 |
| Astellas Pharma US Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ozempic$221
- REXULTI$134
- Diamondback Coronary$133
- TRELEGY ELLIPTA$121
How this compares
$4,341 in reported general payments places this provider in the 75th percentile of 1,469 family medicine providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 78 | $87,996 |
| RybelsusSemaglutide | 41 | $41,133 |
| JardianceEmpagliflozin | 33 | $20,779 |
| FarxigaDapagliflozin Propanediol | 21 | $18,621 |
| TrulicityDulaglutide | 15 | $17,818 |
| EliquisApixaban | 15 | $14,566 |
| LinzessLinaclotide | 11 | $10,894 |
| MounjaroTirzepatide | 11 | $9,683 |
| SynthroidLevothyroxine Sodium | 102 | $6,178 |
| TrintellixVortioxetine Hydrobromide | 12 | $5,662 |
| Pantoprazole Sodium | 199 | $3,322 |
| Testosterone Cypionate | 44 | $2,724 |
| Atorvastatin Calcium | 265 | $2,692 |
| Rosuvastatin Calcium | 152 | $2,085 |
| Ranolazine ErRanolazine | 23 | $1,862 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $654 | $129,129119 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $126 | $27,50126 claims |
| Boehringer IngelheimJardiance | $17 | $20,77933 claims |
| AstraZenecaFarxiga | $102 | $18,62121 claims |
| AbbVieLinzess, Synthroid | $706 | $17,072113 claims |
| PfizerEliquis | $605 | $14,56615 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $34 | $5,66212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,469 family medicine providers in Louisiana.
Other family medicine in Lafayette
- Patrick MooreLafayette$32K
- Clinton GuilloryMonroe$18.5M
- Jason MorrisLake Charles$18M
- Michael SeepLake Charles$9.1M
- William NaboursLake Charles$3M
- Ramon VargasKenner$2.1M
- Stephen JonesNew Orleans$513K
- Joshua WhatleyLake Charles$366K
- Richard JeansonneMandeville$362K
- Kristen ThomasNew Orleans$361K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.